Image pharmaphorum Editor Views & Analysis Why AI equity is the next step for transformational pharma AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approach Views & Analysis Transformational therapies demand a new mindset Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges. Views & Analysis Deep Dive: Research and Development Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel. Views & Analysis Why we need research into the mental health impact of a rare... Rare diseases impact between 3.5%-5.9% of the world’s population. Load more results
Views & Analysis Why AI equity is the next step for transformational pharma AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approach
Views & Analysis Transformational therapies demand a new mindset Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges.
Views & Analysis Deep Dive: Research and Development Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel.
Views & Analysis Why we need research into the mental health impact of a rare... Rare diseases impact between 3.5%-5.9% of the world’s population.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
